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ABSTRACT AG-4 has been characterized as a nicotinic agonist by binding (Ki = 26 ± 1.4 µM) and in vitro
functional assays. The antinociceptive effect of AG-4 was examined in mice and rats, using the hot plate,
abdominal constriction, and paw-pressure tests. In both species, AG-4 (25–150 µg per mouse icv; 100–150
µg per rat icv) produced significant antinociception which was prevented by mecamylamine (2 mg kg–1 ip)
and pempidine (3 mg kg–1 i.p.), but not by atropine (5 mg kg–1 ip), naloxone (1 mg kg–1 ip) and CGP 35348
(100 mg kg–1 ip). In the antinociceptive dose range, AG-4 did not impair mice motor coordination and
spontaneous motility as well as inspection activity. The present results have shown that AG-4 is a com-
pound endowed with antinociceptive properties mediated via nicotinic activation and may be a promising
beginning for new nicotinic agonists. Drug Dev. Res. 41:1–9, 1997. © 1997 Wiley-Liss, Inc.
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INTRODUCTION
Nicotine is a potent modulator of central nervous
system (CNS) function because of its ability to modulate
ion flux and neurotransmitter release, which leads to a
variety of behavioral effects. Nicotine, in fact, has been
shown to produce antinociception in cats [Davis et al.,
1983], mice [Mattila et al., 1968; Mansner, 1972; Phan et
al., 1973; Aceto et al., 1980; Tripathi et al., 1982], rats
[Phan et al., 1973; Sahley and Bernston, 1979; Tripathi et
al., 1982; Martin et al., 1983], dogs [Kamerling et al.,
1982], rabbits, and hamsters [Mattila et al., 1968]. Evi-
dence for an analgesic effect of nicotine in humans has
also been reported [Pomerleau et al., 1984].
AG-4 (2-methyl-5-N,N-dimethylaminomethyl-
cyclopentan-1-one methyl iodide AG-4) (Fig. 1) was re-
ported by Giannella et al. [1980] to be agonist for the
nicotinic receptors (nAChRs). In fact, the equipotent
molar ratio of AG-4 compared to acetylcholine (ACh) is
equal to 1.4 in the frog rectus abdomen and greater than
1,000 in the guinea pig ileum. Within the framework of
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research for new nicotinic agonists, it was decided to use
AG-4 to lead to new compounds that would penetrate
the brain and be more potent and selective for central
nAChRs than the parent compounds. The present work
was designed to verify the pharmacological profile of AG-
4 that has previously been investigated only on periph-
eral nAChRs. In order to delineate the pharmacological
profile of AG-4, its potential analgesic activity was inves-
tigated in the mouse hot plate and abdominal constric-
tion tests and in the rat paw pressure test.
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MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g) and Wistar rats
(200–300 g) from the Morini (San Polo d’Enza, Italy)
breeding farm were used. Fifteen mice and four rats were
housed per cage. The cages were placed in the experi-
mental room 24 h before the test for acclimatization. The
animals were fed a standard laboratory diet and tap wa-
ter ad libitum and kept at 23 ± 1°C with a 12-h light/
dark cycle, light at 7 a.m. All experiments were carried
out according to the guidelines of the European Com-
munity Council for experimental animal care.
Hot Plate Test
The method adopted has been described by
O’Callaghan and Holtzman [1975]. Mice were placed
inside a stainless steel container, thermostatically set at
52.5 ± 0.1°C in a precision water-bath from KW Me-
chanical Workshop, Siena, Italy. Reaction times (sec),
were measured with a stop-watch before and at regular
intervals up to a maximum of 60 min after treatment. The
endpoint used was the licking of the fore or hind paws.
Those mice scoring below 12 and over 18 sec in the pre-
test were rejected (30%). An arbitrary cutoff time of 45
sec was adopted.
Abdominal constriction test
Mice were injected ip with a 0.6% solution of ace-
tic acid (10 ml kg–1), according to Koster et al. [1959].
The number of stretching movements was counted for
10 min, starting 5 min after acetic acid injection.
Paw Pressure Test
The antinociceptive threshold in the rat was deter-
mined with an analgesimeter (Ugo Basile, Varese, Italy),
according to the method described by Leighton et al.
[1988]. Threshold pressure was measured before treat-
ment and 15, 30, and 45 min after treatment. Rats scor-
ing <30 g or >85 g in the test prior to drug administration
were rejected (25%). An arbitrary cutoff value of 250 g
was adopted.
Hole-Board Test
The hole board test consists of a 40-cm-square plane
with 16 flush mounted cylindrical holes (diameter 3 cm)
distributed 4 ×  4 in an equidistant, grid-like manner.
Mice were placed on the center of the board one by one
and left to move about freely for a period of 10 min each.
Two electric eyes, crossing the plane from mid-point to
mid-point of opposite sides, thus dividing the plane into
4 equal quadrants, automatically signaled the move-
ment of the animals on the surface of the plane. Min-
iature photoelectric cells, in each of the 16 holes,
recorded the exploration of the holes (head plunging
activity) by the mice.
Rotarod test
The apparatus consisted of a base platform and a
rotating rod of 3-cm diameter with a non-slippery sur-
face. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into 5 equal
sections by 6 disks. Thus, up to 5 mice were tested si-
multaneously on the apparatus, with a rod-rotating speed
of 16 rpm. The integrity of motor coordination was as-
sessed on the basis of the number of falls from the rod in
30 sec according to Vaught et al. [1985]. The performance
time was measured before and 15, 30, and 45 min after
treatment.
Binding Assay
Cerebral cortices of male Wistar rats (150–200 g) were
dissected on ice. The tissue was homogenized in 50 mM
Tris-HCl buffer (pH = 7.4 at 2°C) containing 120 mM
NaCl, 5 mM KCl, 1 mM MgCl2, and 2.5 mM CaCl2.
The homogenate was centrifuged at 40,000g for 10
min; the pellet was resuspended in ice-cold buffer,
recentrifuged and resuspended again in buffer. Bind-
ing experiments [Pabreza et al., 1990] with [3H]-
cytisine (New England Nuclear, Boston, MA, 39.7 Ci/
mmol) were performed in 250 µl of buffer containing
2 nM [3H]-cytisine, membranes from 15 mg (wet
weight) of tissue and the compounds to be tested. Af-
ter 75 min of incubation at 2°C, separation of bound
from free radioligand was performed by rapid filtra-
tion through Whatman GF/C glass fiber filters, which
were washed three times with ice-cold buffer, dried
and counted in 5 ml of Aquassure (Packard, Downers
Grove, IL). Nonspecific undefined binding in the pres-
ence of 10 µM (–)nicotine bitartrate and was, routinely,
about 10% of the total binding. Ki values were calcu-
lated from Cheng-Prusoff [1973] using 1.5 nM as the
Kd for [3H]-cytisine, determined by previous satura-
tion experiments.
Fig. 1. Chemical structure of AG-4.
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Isolated Guinea Pig Ileum
The action of AG-4 was examined at neuronal
nAChRs; 2-cm segments of the terminal portion of the
guinea pig ileum were suspended under 1g resting ten-
sion in 10-ml organ baths containing Krebs solution (mM):
NaCl (137), KCl (2.7), CaCl2 (1.8), MgCl2 (1.05), NaH2PO4
(0.42), NaHCO3 (11.9), and glucose (5.6). The solution
was aerated with gas mixture of 95% O2, 5% CO2, and
maintained at 37°C. After 1 h of equilibration, the tis-
sues were exposed to DMPP (1,1-dimethyl-4-phenyl-
piperazinium jodid) or AG-4. Concentration response
curves were constructed non cumulatively. Tissues were
exposed to drugs for 30 s with at least 5 min rest between
exposures. Effects of the antagonist hexamethonium 30
µM was investigated after a 30 min equilibration.
Intracerebroventricular Injection Technique
Intracerebroventricular (icv) administration was
performed under ether anaesthesia using isotonic saline
as a solvent, according to the method described by Haley
and McCormick [1957]. Briefly, during anaesthesia, mice
and rats were grasped firmly by the loose skin behind
the head. A 0.4-mm external diameter, a hypodermic
needle attached to a 10-µl syringe was inserted perpen-
dicularly through the skull at a depth of no more than 2
mm into the brain of the mouse and 4 mm into the brain
of the rat, where 5 µl (mice) or 10 µl (rats) was then ad-
ministered. The injection site was 1.5 mm (mice) or 2.5
mm (rats) from either side of the midline on a line drawn
through to the anterior base of the ears. To ascertain that
the drugs were administered exactly into the cerebral
ventricle, some mice and rats were icv injected with 5–
10 µl of diluted 1:10 Indian ink and their brains exam-
ined macroscopically after sectioning. Intraplantar
injections of carrageenan were performed by injecting
100 µl of a suspension in sterile saline solution of 0.5%
carrageenan in the rat hind paw.
Reagents and Compounds
The following drugs were used: AG-4 was a kind
gift of Professor Giannella, University of Camerino; at-
ropine sulfate, pempidine hydrochloride, naloxone
hydrochloride (Sigma, St. Louis, MO) morphine hydro-
chloride (U.S.L. 10/D, Florence); CGP 35348 and (±)-
baclofen (Novartis, Basle, CH); (+)-amphetamine sulfate
(Recordati); mecamylamine hydrochloride, McN-A-343
(RBI); DMPP (1,1-dimethyl-4-phenyl-piperazinium
jodide), nicotine hydrogentartrate (Fluka); [3H]-cytisine
(New England Nuclear): 39.7 Ci/mmol). Other chemi-
cals were of the highest quality commercially available.
All drugs were dissolved in isotonic (NaCl 0.9%) saline
solution. Drug concentrations were prepared in such a
way that the necessary dose could be administered in a
volume of 10 ml kg–1 by subcutaneous (sc), intraperito-
neal (ip) or 5 µl per mouse by icv injection.
Statistical Analysis
All experimental results are given as the mean
±s.e.m. An analysis of variance (ANOVA), followed by
Fisher’s PLSD procedure for post-hoc comparison, was
used to verify significance between two means. Data were
analyzed with the StatView software for the Macintosh
(1992). P-values of <0.05 were considered significant.
RESULTS
Binding assay
The Ki value of AG-4 was 26 ± 1.4 µM (mean ±
s.e.m., n = 4) in comparison with nicotine, which had a
Ki value of 8.2 ± 0.5 nM at displacing the binding of [3H]-
cytisine sites. (Data not shown.)
Isolated Guinea Pig Ileum
AG-4 was able to constrict guinea pig isolated il-
eum fragments with an EC50 of 3.05 µM. This effect
was blocked by the nicotinic antagonist hexametho-
nium 30 µM. The concentration-response curves for
AG-4 and DMPP, used as reference drug, are illus-
trated in Figure 2.
Antinociceptive Activity of AG-4
AG-4, as shown in Figure 3, produced a dose-de-
pendent increase in the pain threshold in the mouse hot-
plate test after icv (25–150 µg per mouse) administration.
The direct injection of AG-4 into the cerebral ventricles
Fig. 2. Dose-response curves of AG-4 and DMPP on guinea pig ileum.
Each point represents the mean ±s.e.m. of at least four experiments.
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was needed since this compound is cationic and does not
cross the blood brain barrier. The antinociceptive effect
of AG-4 peaked 15–30 min after injection and then di-
minished. The areas under the curve of the anti-
nociception induced by AG-4 (150 µg per mouse icv),
nicotine (1.5 µg per mouse icv), morphine (2.0 µg per
mouse icv), and McN-A-343 (30 µg per mouse icv) are
reported in Figure 4.
Figure 5 illustrates the analgesic effect of AG-4 in
the mouse acetic acid abdominal constriction test. In this
test AG-4 induced an increase in the pain threshold in a
dose-dependent manner starting from the dose of 50 µg
per mouse icv.
AG-4 was able to produce an increase in the pain
threshold not only in mice but also in rats. In the paw
pressure test AG-4 administered icv at the dose of 100
and 150 µg per rat, induced antinociception starting 15
min after injection and persisting up to 45 min (Table 1).
Antagonism of the AG-4-Induced Antinociception
In the mouse hot-plate test, the antinociceptive
effect of AG-4 (100 µg per mouse icv) was not antago-
nized by atropine (5 mg kg–1 ip), naloxone (1 mg kg–1
ip) and CGP-35348 (100 mg kg–1 ip) in the mouse hot
plate test as reported in Table 2. Conversely, mecamy-
lamine (2 mg kg–1 ip) and pempidine (3 mg kg–1 ip)
were able to completely prevent AG-4 antinociception
in both hot plate (Table 3) and abdominal constriction
tests (Fig. 5). All antagonists were injected 15 min
before AG-4, with the exception of CGP 35348, in-
jected 5 min before AG-4.
Figure 6 shows that the doses of 2 mg kg–1 ip and 3
mg kg–1 ip of mecamylamine and pempidine, respectively,
were needed to completely antagonize the antino-
ciception induced by nicotine (1.5 µg per mouse icv) and
AG-4 (100 µg per mouse icv) without interfering in any
way with morphine (2 µg per mouse icv) and baclofen (4
mg kg–1 sc) evoked analgesia.
Evaluation of the AG-4 Effect on Spontaneous
Activity and Motor Coordination
The motor coordination of mice treated with AG-4
was evaluated by using the rota-rod test (Table 3), while
their spontaneous activity and inspection activity were
investigated by using the hole-board test (Fig. 7). The
rotarod performance of mice treated with 100–150 µg
per mouse icv of AG-4, was not impaired in comparison
with controls (Table 4). On the contrary, AG-4 adminis-
tered at higher doses (200 µg per mouse icv) produced a
significant impairment of the rota-rod performance (Table
3). The number of falls by control animals progressively
decreased at every measurement since the mice learned
how to balance on the rotating rod. The spontaneous motil-
ity and exploratory behavior of mice was not modified by
treatment with AG-4 (100–150 µg per mouse icv) as re-
vealed by the hole-board test (Fig. 7). In the same experi-
mental conditions, amphetamine (2 mg kg–1 sc) produced
an increase of both parameters evaluated (Fig. 7).
Fig. 3. Dose-response curves of AG-4 in the mouse hot-plate test. The
doses are expressed as µg per mouse icv. Vertical lines show s.e.m. ^P
< 0.05; *P < 0.01 in comparison with saline controls. Each point repre-
sents the mean of at least 10 mice.
Fig. 4. Area under the curve of the analgesic effect of AG-4 in compari-
son with nicotine, morphine, and McN-A-343 in hot plate test. The
antinociceptive responses were recorded 15–45 min after administration
of AG-4, morphine, and McN-A-343 and 5–30 min after nicotine injec-
tion. Numbers inside the columns indicate the number of mice.
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DISCUSSION
Early studies of AG-4 characterized the com-
pound as a nicotinic agonist [Giannella et al., 1980].
Our research confirms and extends this finding. AG-4
showed a moderate affinity for nAChR, labelled with
[3H]-cytisine and, furthermore, was able to constrict
the isolated guinea pig ileum.
AG-4 was also able to induce antinociception in
laboratory animals. AG-4-induced antinociception was
elicited regardless of which noxious stimulus was used:
thermal (hot-plate), chemical (abdominal constriction test)
and mechanical (paw pressure test). The pharmacologi-
cal actions of AG-4 were obtained without producing any
visible modification of the animals’ gross behavior. More-
over, AG-4 treated mice retained their motor coordina-
tion on the rota-rod test, normal spontaneous motility,
and exploratory behavior as revealed by the hole-board
test. However, at doses three times higher than those ef-
fective as analgesic, AG-4 showed marked side effects
such as convulsions (data not shown).
AG-4 antinociception was found to be dependent
on central nicotinic system activation, since it was pre-
vented by the nicotinic antagonists mecamylamine and
pempidine, administered at doses able to antagonize
the antinociception induced by nicotine without in-
terfering in any way with morphine and baclofen
evoked analgesia.
The involvement of other neurotransmitter sys-
Fig. 5. Dose-response curves of AG-4 and effect of both mecamylamine
(2 mg kg–1 ip) and pempidine (3 mg kg–1 ip) pretreatments on
antinociception induced by AG-4 (100 µg per mouse icv) in the mouse
abdominal constriction test. Mecamylamine and pempidine were injected
15 min before AG-4 treatment. The antinociceptive responses were re-
corded 10–20 min after AG-4 administration. Vertical lines show s.em.
^P < 0.05; *P < 0.01 in comparison with saline-treated controls; °P <
0.01 in comparison with saline-AG-4 treated mice. Numbers inside the
columns indicate the number of mice.
tems in AG-4 antinociception can be ruled out since
the opioid antagonist naloxone, the muscarinic antago-
nist atropine and the γ-aminobutyric acid-B (GABAB
antagonist, CGP-35348, were all unable to prevent the
effect of AG-4. The doses and administration sched-
ules of the above-mentioned drugs were ideal for pre-
venting antinociceptions induced, respectively, by
morphine [Ghelardini et al., 1992], oxotremorine
[Bartolini et al., 1987], and the GABAB agonist,
baclofen [Malcangio et al., 1991].
AG-4, like nicotine, demonstrated antinociception
properties, but with greater efficacy than that exerted by
nicotine. Furthermore, AG-4 is endowed with a longer
lasting analgesic effect than nicotine even if it starts 10
min later. However, the potency of AG-4 is 100 times
lower than that of nicotine and this reflects the lower
binding affinity of AG-4 for nicotinic receptors compared
to nicotine. The analgesic effect of AG-4 was also com-
pared with that induced by well-known analgesic drugs
such as morphine, nicotine, and the selective M1 antago-
nist McN-A-343 at the highest doses that did not impair
rota-rod performance. By comparing the areas under the
curve, the antinociceptive efficacy of AG-4 (150 µg per
mouse icv) was almost equal to those exerted by mor-
phine (2.0 µg per mouse icv) and McN-A-343 (30 µg per
mouse icv), but greater than that induced by nicotine (1.5
µg per mouse icv).
In summary, our results have shown that the new
nicotinic agonist AG-4 is able to produce antinociception
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TABLE 2. Effects of Atropine, Naloxone, CGP-35348, Mecamylamine, and Pempidine on Antinociception Caused by AG-4 in the Mouse Hot
Plate Test†
Licking latency (s)
Before After treatment
Pretreatment Treatment µg icv pretreatment 15 min 30 min 45 min
Saline Saline 13.6 ± 0.7 14.4 ± 1.0 13.9 ± 0.9 15.1 ± 0.7
10 ml kg–1 ip AG-4 100 14.1 ± 0.8 27.5 ± 1.4* 26.7 ± 1.7* 22.4 ± 1.8*
Atropine Saline 13.8 ± 0.9 15.3 ± 1.5 13.9 ± 2.1 15.8 ± 1.9
5 mg kg–1 ip AG-4 100 14.3 ± 1.2 26.7 ± 1.4* 27.4 ± 2.0* 20.6 ± 1.7*
Naloxone Saline 13.9 ± 0.8 13.5 ± 1.2 14.6 ± 1.7 14.3 ± 1.8
1 mg kg–1 ip AG-4 100 14.2 ± 0.9 27.3 ± 2.1* 25.8 ± 2.2* 19.4 ± 1.9**
CGP 35348 Saline 13.6 ± 0.6 11.5 ± 1.2** 13.1 ± 1.7 12.9 ± 1.8
100 mg kg–1 ip AG-4 100 14.5 ± 0.8 25.1 ± 1.8* 27.8 ± 2.0* 21.5 ± 1.4*
Mecamylamine Saline 14.4 ± 1.0 14.9 ± 1.7 14.1 ± 1.6 14.7 ± 1.6
2 mg kg–1 ip AG-4 100 13.5 ± 0.9 15.6 ± 2.0‡ 15.8 ± 1.4‡ 16.3 ± 1.3‡
Pempidine Saline 15.0 ± 0.6 14.7 ± 1.6 14.9 ± 1.7 15.3 ± 1.6
3 mg kg–1 ip AG-4 100 14.3 ± 0.8 16.8 ± 1.4‡ 17.3 ± 2.0‡ 15.9 ± 1.5‡
†The number of mice is shown in parentheses. The number of mice ranged from 8 to 18, with the exception of saline–saline, which numbered 24.
*P < 0.01.
**P < 0.05 in comparison with saline–saline.
‡P < 0.01 versus saline- AG-4 treated mice.
TABLE 3. Effect of AG-4 in the Mouse Rota-rod Test†
No. of falls (30s)
Before After treatment
Treatment Dose treatment 15 min 30 min 45 min 60 min
Saline 5 µl icv 3.6 ± 0.3 2.4 ± 0.3 1.8 ± 0.2** 1.3 ± 0.1** 1.3 ± 0.1**
AG-4 100 µg icv 3.2 ± 0.5 2.6 ± 0.3 2.0 ± 0.3** 1.5 ± 0.3** 1.6 ± 0.2**
AG-4 150 µg icv 3.4 ± 0.4 2.4 ± 0.4 2.2 ± 0.3** 1.8 ± 0.4** 1.2 ± 0.1**
AG-4 200 µg icv 3.5 ± 0.4 3.9 ± 0.5* 4.0 ± 0.5* 3.4 ± 0.4* 2.3 ± 0.2*,**
†Each value represents the mean of at least 8 mice.
*P < 0.01 in comparison with saline controls.
**P < 0.01 in comparison with the respective pre-test value.
TABLE 1. Antinociception Exerted by AG-4 in the Paw-Pressure Test in the Rat and Antagonism by Mecamylamine†
Paw pressure (g)
Treatment Dose Before After treatment
Pretreatment (icv) (µg/mouse) pretreatment 15 min 30 min 45 min
Saline Saline 58.9 ± 4.2 60.2 ± 3.1 57.8 ± 3.2 60.3 ± 3.4
10 ml kg–1 ip (8) (8) (8) (8)
Saline ip AG-4 25 60.6 ± 3.0 68.7 ± 4.4 56.7 ± 4.2 55.6 ± 3.8
(5) (5) (5) (5)
AG-4 100 55.6 ± 3.8 112.6 ± 5.1* 107.8 ± 4.2* 73.5 ± 4.5**
(6) (6) (6) (6)
AG-4 150 61.2 ± 3.6 107.5 ± 5.5* 96.6 ± 5.3* 76.6 ± 5.1**
(5) (5) (5) (5)
Mecamylamine Saline 58.4 ± 3.5 60.3 ± 4.1 55.8 ± 3.8 64.1 ± 3.2
2 mg kg–1 ip (10) (10) (10) (10)
AG-4 100 60.2 ± 3.0 67.2 ± 5.4† 66.2 ± 4.3‡ 62.1 ± 4.0
(5) (5) (5) (5)
†The number of rats is shown in parentheses.
*P < 0.01.
**P < 0.05 in comparison with saline–saline.
‡P < 0.01 versus saline–AG-4.
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Fig. 6. Effect of mecamylamine (A) and pempidine (B) adminis-
tered ip on antinociception induced by nicotine (1.5 µg per mouse
icv), AG-4 (100 µg per mouse icv), morphine (2 µg per mouse icv),
and baclofen (4 mg kg–1 sc) in the mouse hot-plate test. Mecamy-
lamine and pempidine were injected ip 10 min before nicotine and
AG-4 and 5 min before morphine and baclofen. Nociceptive re-
sponses were recorded 10 min after nicotine injection, 15 min after
morphine and AG-4 administration and 30 min after baclofen injec-
tion. Numbers inside the columns indicate the number of mice.
Vertical lines show s.e.m. *P < 0.01 in comparison with saline-treated
controls. oP < 0.01 versus nicotine or AG-4 treated mice.
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